Search

BioMarin Pharmaceutical Inc

Отворен

СекторЗдравеопазване

64.25 -3.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.97

Максимум

66.7

Ключови измерители

By Trading Economics

Приходи

-61M

45M

Продажби

224M

990M

P/E

Средно за сектора

179.811

56.597

EPS

0.9

Марж на печалбата

4.523

Служители

3,221

EBITDA

50M

222M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+41.54% upside

Дивиденти

By Acuity

Следващи печалби

26.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.3B

13B

Предишно отваряне

67.43

Предишно затваряне

64.25

Настроения в новините

By Acuity

23%

77%

29 / 339 Класиране в Healthcare

BioMarin Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.09.2026 г., 20:07 ч. UTC

News
Event

BioMarin Pharmaceutical shares are higher following new data from the Phase 3 CANOPY-HCH-3 study on VOXZOGO, published in the New England Journal of Medicine.

8.09.2026 г., 19:51 ч. UTC

BioMarin Pharmaceutical Inc. shares are lower today amid significant declines in the Biotechnology sub-sector, breaking a recent trend of higher daily closes.

4.09.2026 г., 20:07 ч. UTC

BioMarin Pharmaceutical Inc shares are higher in Friday's session, despite earlier pullbacks. No specific news was identified to explain the movement.

3.09.2026 г., 19:46 ч. UTC

News
Social Media

BioMarin Pharmaceutical completes a $275 million acquisition, impacting its strategic positioning. Shares are lower during Thursday's session amid broader biotech M&A activity.

2.09.2026 г., 23:01 ч. UTC

BioMarin Pharmaceutical Inc. shares declined in after-market trading, reversing earlier gains amid broader market concerns tied to U.S.-Iran tensions and rising oil prices.

1.09.2026 г., 19:46 ч. UTC

News

BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics today. Despite this, shares are lower amid integration concerns and ongoing clinical evaluations.

31.08.2026 г., 21:01 ч. UTC

BioMarin Pharmaceutical shares are lower in after-market trading amid cautious market sentiment influenced by hawkish comments from Fed Chair Kevin Warsh on inflation.

24.08.2026 г., 19:26 ч. UTC

Social Media

BioMarin Pharmaceutical announced its $275 million acquisition of Alesta Therapeutics. Shares are trading lower amid ongoing market volatility and geopolitical tensions.

21.08.2026 г., 19:16 ч. UTC

Biomarin Pharmaceutical Inc shares are lower today, despite earlier gains. Broader market volatility linked to rising crude oil prices may be influencing sentiment.

20.08.2026 г., 19:16 ч. UTC

News
Social Media

BioMarin Pharmaceutical shares are lower despite BMO initiating coverage with an Outperform rating and a price target of $98.

19.08.2026 г., 23:51 ч. UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

18.08.2026 г., 23:41 ч. UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, reflecting broader market declines amid profit-taking in technology and concerns over rising bond yields.

17.08.2026 г., 19:16 ч. UTC

News

BioMarin shares are lower despite price target increases from Barclays and Piper Sandler, reflecting ongoing downward performance trends in recent sessions.

14.08.2026 г., 20:06 ч. UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13.08.2026 г., 22:36 ч. UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12.08.2026 г., 23:01 ч. UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11.08.2026 г., 19:56 ч. UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10.08.2026 г., 23:26 ч. UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7.08.2026 г., 23:16 ч. UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6.08.2026 г., 23:02 ч. UTC

News

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5.08.2026 г., 23:56 ч. UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4.08.2026 г., 19:46 ч. UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3.08.2026 г., 23:31 ч. UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31.07.2026 г., 20:06 ч. UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30.07.2026 г., 19:08 ч. UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29.07.2026 г., 18:14 ч. UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28.07.2026 г., 18:02 ч. UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27.07.2026 г., 19:01 ч. UTC

News

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24.07.2026 г., 15:46 ч. UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22.07.2026 г., 23:31 ч. UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

Сравнение с други в отрасъла

Ценова промяна

BioMarin Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

41.54% нагоре

12-месечна прогноза

Среден 94 USD  41.54%

Висок 124 USD

Нисък 60 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за BioMarin Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

15

Купи

5

Задържане

0

Продай

Настроение

By Acuity

29 / 339 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat